Kisunla®️ (Donanemab) is an intravenous medicine that has shown great results
In Brazil, the treatment is currently available only in high diagnosis, which is part of the Dasa
Anvisa has recently approved the use of Kisunla®️ (Donanemab), an intravenous drug that represents an important progress in the treatment of Alzheimer’s initial phase. Therapy slows down cognitive decline by acting on beta-amyloid and tau proteins, associated with the progress of the disease.
The results of the drug in Alzheimer
The results of the Trailblazer-Alz2 clinical study, published in the New England Journal of Medicine, showed that the drug has significantly reduced the progression of the disease. Among the participants, 30% showed an improvement in six months and 66% had a significant reduction in amyloid signs within 12 months.
In Brazil, the treatment is currently available only in high diagnosis, which is part of Dasa. From September, the therapy will be offered in Unit of San Paolo and Rio de Janeiro.
According to the neurologist Diogo Haddad, coordinator of the high center of diagnostic memory, “having access to the drug in Brazil means offering patients with Alzheimer’s and their families the opportunity to act for the first time in the pathophysiology of the disease. It is a treatment that has requested a rigorous follow -up medical, which has already shown that they translate into interesting clinical studies for a group of specific patients with the first diseases.”
Indication
Doctors indicate the therapy for initial cognitive paintings, with monthly infusions for 12-18 months, always under supervision. Each session lasts about 30 minutes, followed by another 30 minutes of observation. Treatment requires monitoring with magnetic resonance imaging and doctors do not recommend it for people with previous cerebrovascular diseases.
Experts also highlight the concern for the increase in diagnostics at the most initial age, including patients under 60 years of age and even rare cases of about 40 years. In Brazil, between 75% and 95% of Alzheimer cases remain without diagnosis, in particular among young people.
In addition to the application of the drug, at high diagnosis offers a clinical staff specialized in neurodegenerative diseases and a large portfolio of related exams in search of Alzheimer’s, such as blood and CSF, as well as advanced imaging tests.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
